Related Experiment Videos
Pharmacogenomic contribution to drug response
Roshawn G Watson1, Howard L McLeod
1UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7361, USA.
Cancer Journal (Sudbury, Mass.)
|March 24, 2011
Summary
Personalized cancer treatments are advancing, using molecular predictors to guide therapy for breast and colorectal cancers. Integrating genomic and clinical data improves treatment selection and toxicity prediction.
Area of Science:
- Oncology
- Pharmacogenomics
- Molecular Diagnostics
Background:
- Individualized cancer therapy shows significant progress, particularly for breast and colorectal cancers.
- Molecular predictors are key for determining treatment aggressiveness and predicting recurrence.
- Altered drug metabolism and target variations influence therapeutic efficacy and toxicity.
Purpose of the Study:
- To provide insights into targeted cancer therapy guided by patient-specific molecular characteristics.
- To review the role of pharmacogenomics in optimizing cancer treatment strategies.
- To highlight the integration of molecular and clinical data for improved patient outcomes.
Main Methods:
- Review of molecular predictors for disease recurrence (e.g., Mammaprint, OncotypeDX).
- Analysis of genetic variations affecting drug activation and targets (e.g., DPYD, CYP2D6, UGT1A1, TYMS, EGFR, KRAS).
- Discussion on integrating pharmacogenomic and clinical data.
Main Results:
- Molecular predictors objectively determine therapy aggressiveness.
- Genetic variations inform dose modifications and identify target alterations.
- Pharmacogenomic insights guide personalized treatment selection.
Conclusions:
- Patient-specific molecular profiles are increasingly guiding cancer therapy.
- Integration of pharmacogenomic and clinical data offers powerful predictive tools.
- Stratifying responders and non-responders, and predicting toxicity are key benefits.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...